Actuate Therapeutics (ACTU) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Actuate Therapeutics (ACTU) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 89.7% versus a loss of 89.8%. Actuate Therapeutics is the larger company by market cap ($16.3 million vs $13.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | KPTI |
|---|---|---|
| Share price | $0.679 | $0.60 |
| Market cap | $16.31M | $13.61M |
| 1-day change | -6.24% | -6.98% |
| YTD return | -88.17% | -91.85% |
| 1-year return | -89.71% | -89.83% |
| 5-year return | — | -99.28% |
| EPS (TTM) | $-0.87 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $10.99 |
| 52-week low | $0.604 | $0.60 |
| Distance from 52-week high | -92.00% | -94.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +1620.18% | +1108.33% |
| Average volume | 391.80K | 1.70M |
| Shares outstanding | 24.01M | 22.68M |
| Employees | 12 | 228 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Healthcare · Biotechnology · 12 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Healthcare · Biotechnology · 228 employees
ACTU vs KPTI FAQ
Which is bigger, Actuate Therapeutics or Karyopharm Therapeutics?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $16.31M compared with $13.61M for Karyopharm Therapeutics (KPTI).
Which stock has performed better over the past year, ACTU or KPTI?
ACTU returned -89.71% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Karyopharm Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.